The written stability testing program is not followed.
Inspection Record
Granules Pharmaceuticals Inc. — FDA 483 Findings
Inspectors David A Oluwo · Ofuje D DaniyanThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Buildings used in the holding of a drug product are not maintained in a good state of repair.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Batch production and control records do not include complete information relating to the production and control of each batch.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Shimoga Chemicals2026-01-23 · US FDASimilar to finding 4 Batch production and control records do not include complete information relating to the production and control of each batch.
- VitaCare Labs Inc.2025-05-16 · US FDASimilar to finding 1 The written stability testing program is not followed.
- L. Perrigo Co2015-07-10 · US FDASimilar to finding 1 The written stability testing program is not followed.
- Gilead Sciences Inc.2015-07-17 · US FDASimilar to finding 2 Buildings used in the holding of a drug product are not maintained in a good state of repair.
- LCC Ltd.2024-03-22 · US FDASimilar to finding 4 Batch production and control records do not include complete information relating to the production and control of each batch.
A record as of the US FDA document published on 2026-10-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.